TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05919251

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ageless Grace
Description: This unique program attempts to combine multiple aspects that easily fit together including music and a group setting for socialization. The use of music to improve cognition as has been shown in other research studies to improve participation in exercise program. By linking cognitive retraining, low intensity exercise, group activities and music, the researchers of this project can determine if a movement program with these attributes can benefit individuals as a program of wellness once their rehabilitation plans have been completed. The researchers are specifically interested in the effect on balance, activity and incidence of falls in people with chronic stroke. Additionally, the researchers will investigate the differences that this structured program will make on older adults who will act as a comparison group. This will bring insight into some of the additional challenges that people with stroke encounter on a daily basis.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ageless Grace
Description: This unique program attempts to combine multiple aspects that easily fit together including music and a group setting for socialization. The use of music to improve cognition as has been shown in other research studies to improve participation in exercise program. By linking cognitive retraining, low intensity exercise, group activities and music, the researchers of this project can determine if a movement program with these attributes can benefit individuals as a program of wellness once their rehabilitation plans have been completed. The researchers are specifically interested in the effect on balance, activity and incidence of falls in people with chronic stroke. Additionally, the researchers will investigate the differences that this structured program will make on older adults who will act as a comparison group. This will bring insight into some of the additional challenges that people with stroke encounter on a daily basis.
Study: NCT02216162

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arm A: adapted physical activity + enhanced geriatric follow-up
Description: Patients have 3-monthly geriatric follow-up with biological tests, anti-aromatase agents blood dosing and a clinical assessment (M3 to M9, M15 to M22 and M27 to M33). Musculoskeletal adverse events and quality of life level will be reported and analgesic treatment adapted. Patients will be proposed weekly Taï-Chi exercises to improve joint flexibility, muscular tonus and balance and reduce fall risk.~A broader geriatric assessment including functionality, gait analysis and nutrition will be performed each year (M12, M24 and M36).

Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: Usual clinical follow-up
Study: NCT01755637

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albendazole
Description: Albendazole tablets 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole
Description: Albendazole tablets 400 mg
Study: NCT00762684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-559
Description: TAK-559 32 mg, tablets, orally, once daily for up to 26 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-559 placebo-matching tablets, orally, once daily for up to 26 weeks.
Study: NCT02324023

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound
Description: All patients will be evaluated by EUS and CE-EUS, using radial EUS instruments. The EUS scope will be inserted under direct vision, passed by the tumour and examination should begin during withdrawal at 7.5 MHz. The tumour will be characterized describing its echogenicity, echo structure, size, extent into the bowel wall and surrounding structures, and it will be staged using the modification of the TNM classification, based on a five-layer intestinal wall model. The presence/absence of power Doppler signals will be noted. For CE-EUS parameters for objective measurement of tumour perfusion will include maximum intensity of enhancement, mean transit time, time to peak (wash-in time), wash-in slope, area under the curve, representing indirectly blood flow or blood volume in CRC patients.
Study: NCT01388530

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMS 7500 Digital Muscle Stimulator
Description: A standard FDA approved transcutaneous electrical nerve stimulation (TENS) unit will be used to apply low intensity stimulation to the trigeminal nerves during sleep.
Study: NCT03537053

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A plan to Move a Little and Often
Description: The intervention content is reported using the behaviour change technique (BCT) Taxonomy v1 (Michie, et al. 2013). The video will contain the BCT: information about health consequences. The booklet will consist of BCTs: self-monitoring of behaviour, goal setting behaviour, action planning, commitment, social support (practical), self-talk, and mental rehearsal of successful performance. Lastly, usage of the Facebook group will include BCTs: commitment, and social support unspecified, practical and emotional.~Mental rehearsal, goal setting behaviour and action planning will be delivered through mental simulation exercises (Taylor, et al. 1998). BCTs self-monitoring of behaviour, goal setting behaviour, and commitment will be delivered using implementation intentions (Gollwitzer 1993).
Study: NCT05400460

Intervention type: OTHER
Group type: OTHER
Intervention: Educate patients on return to sports and the importance of quadriceps strength
Description: Patients were interviewed by telephone preoperatively, 6 months postoperatively, and 1 year postoperatively to ask about Tegner scores and to encourage reasonable return to sports from 6 months postoperatively.~Inform patients of the possibility of osteoarthritis in patients undergoing ACL reconstruction preoperatively, 6 months postoperatively, and 1 year postoperatively in telephone interviews.Tell the patient that return to sports and quadriceps strength is a must if the knee cartilage damage is to improve.
Study: NCT01613092

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Incremental
Description: Cefazolin and Vancomycin pre-op, bacitracin wash and postoperative cefalexin or clindamycin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin
Description: Preoperative antibiotic
Study: NCT01774916

Intervention type: GENETIC
Group type: OTHER
Intervention: blood samples

Intervention type: GENETIC
Group type: OTHER
Intervention: blood samples
Study: NCT00548912

Intervention type: DRUG
Group type: OTHER
Intervention: Spironolactone
Study: NCT03069638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Intranasal administration of dexmedetomidine as a procedural sedation (intra-articular joint injection)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Intranasal administration of dexmedetomidine as a procedural sedation (intra-articular joint injection)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sedatives/Hypnotics,Other
Description: Inhaled dinitrous oxide as procedural sedation (intra-articular joint injection)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sedatives/Hypnotics,Other
Description: Inhaled dinitrous oxide as procedural sedation (intra-articular joint injection)
Study: NCT02719054

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy: Alter of negative thinking, positive thinking and social support and psychosocial stimulation: play stimulation and parenting
Description: A:Cognitive Behavioral Therapy specifically focused on changing thinking style toward positive and not associated with any medication. CBT found to be effective in managing or treating not only depression, also a variety of other conditions-e.g. mood, personality, stress, eating habit, tic etc.~B: Psycho social stimulation will follow a set of culturally appropriate, semi-structured, child's age appropriate curriculum.
Study: NCT01161836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iniparib
Description: Solution for infusion~60-minute intravenous infusion
Study: NCT04020874

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HuTT-2x
Description: tackling and blocking training twice/week

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HuTT-4x
Description: tackling and blocking training four times/week
Study: NCT00852930

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laser and MLD combined
Description: The intervention is therapist administered laser and mld treatment combined

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laser alone
Description: The intervention is therapist administered laser

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: manual lymphatic drainage
Description: The intervention is therapist administered manual lymphatic drainage
Study: NCT01368068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tibolone
Description: 2.5mg/oral/daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: 10mg/oral/daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Natvia
Description: serving size: 0.09g per tablet
Study: NCT02183389

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356
Study: NCT01565525

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maternal focused intervention
Description: This is a series of information given to mothers at child's well child visits (6 in all) starting at the newborn visit focused in maternal eating habits, using the mother as a potential 'agent of change' for the family and infant in modeling healthy eating habits.
Study: NCT03289000

Intervention type: DEVICE
Intervention: iTotal Posterior Stabilized (PS) Knee Replacement System
Description: Patient-specific posterior stabilized total knee replacement and patient specific surgical jigs
Study: NCT00593073

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic tailored messaging
Description: Tailored CRC message based on patient screening barriers, preferences and attitudes and reminder to get screened.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: General Reminder Message
Description: General CRC health education message and reminder to get screened.
Study: NCT03698019

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study: NCT04180449

Intervention type: OTHER
Intervention: Screening for dysphagia along clinical routine
Description: Screening for dysphagia using the water swallow test in intermediate care unit patients

Intervention type: OTHER
Intervention: Screening for dysphagia along clinical routine
Description: Screening for dysphagia using the water swallow test in intermediate care unit patients
Study: NCT01565525

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ounce of Prevention
Description: This intervention is given via a series of handouts given to mothers at their child's well visit from newborn period to one year of age, focusing on serving size and frequency and the introduction of new foods.
Study: NCT03982225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyene phosphatidylcholine injection
Description: Formulated as an injectable solution containing Polyene Phosphatidylcholine at two concentration of 25 mg/mL and 50 mg/mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyene phosphatidylcholine injection
Description: Formulated as an injectable solution containing Polyene Phosphatidylcholine at two concentration of 25 mg/mL and 50 mg/mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyene phosphatidylcholine injection
Description: Formulated as an injectable solution containing Polyene Phosphatidylcholine at two concentration of 25 mg/mL and 50 mg/mL.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Phosphate buffered saline placebo for injection
Study: NCT02087553

Intervention type: BIOLOGICAL
Intervention: Infusion of albumin/saline
Description: (non-experimental) albumin/saline infusion
Study: NCT00583453

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: Celecoxib 200 mg capsule~1. capsule the night before surgery~2. capsules the morning of surgery~1 capsule the night of surgery~1 capsule twice daily for 10 days immediately after the surgery
Study: NCT02111811

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Veterans Work and Health Initiative
Description: CBT based intervention focused on work productivity
Study: NCT01923610

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Biological/Vaccine: MVA-B Modified Pox virus, strain MVA clade -B (expressing HIV-1 Bx08gp120 and IIIB gagpolnef)~-\~ 1 x 10e8 pfu/ml 3 immunisations at week 0, 4 and 16
Study: NCT01458769

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: C-10276
Description: C-10276 200 mg, C-10276 400 mg, Reyataz 400 mg oral, single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: C-10276
Description: C-10276 300 mg, CTP-518 100 mg with C-10276 300 mg, C-10276 400 mg oral, single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: C-10297
Description: C-10297 200 mg, oral, single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: C-10299
Description: C-10299 200 mg, oral, single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: C-10297
Description: C-10297 400 mg, Reyataz 400 mg, C-10297 600 mg, oral, single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: C-10299
Description: C-10299 400 mg, Reyataz 400 mg, C-10299 600 mg, oral, single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: C-10276
Description: C-10276 600 mg, Reyataz 400 mg, Reyataz 600 mg, oral, single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reyataz®
Description: Reyataz 400 mg, oral, single dose Reyataz 600 mg, oral, single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reyataz®
Description: Reyataz 400 mg, oral, single dose Reyataz 600 mg, oral, single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reyataz®
Description: Reyataz 400 mg, oral, single dose Reyataz 600 mg, oral, single dose
Study: NCT02851446

Intervention type: OTHER
Intervention: measure dyspnoea> Borg 7

Intervention type: OTHER
Intervention: measure dyspnoea> Borg 7
Study: NCT02270177

Intervention type: OTHER
Group type: OTHER
Intervention: Telemedicine, videoconsultation
Description: We are investigating the use of videoconsultations (through telemedicine technology) in patients with primary headaches.
Study: NCT02957773

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Qigong and art activities
Description: Participants join a 90-minute session of integrated Qigong and art activity consisting of 30 minutes Qigong followed by 60 minutes art activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Art activities
Description: Participants join a 90-minute session that consists of 60-minute art activities followed by 30 minutes daily activities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Qigong
Description: Participants join a 90-minute session that consists of 30-minutes Qigong exercise followed by 60 minutes daily activities (watching television, reading or sitting together).
Study: NCT00583453

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule~1. capsule the night before surgery~2. capsules the morning of surgery~1 capsule the night of surgery~1 capsule twice daily for 10 days immediately after the surgery
Study: NCT03657550

Intervention type: DRUG
Group type: OTHER
Intervention: Levamlodipine, Amlodipine
Description: In Part 1, this group of subjects were treated with a single dose of 5 mg levamlodipine maleate tablets (Test Product), then crossed over to receive a single dose of 10 mg Amlodipine Besylate Tablet NORVASC® (Reference Product) under fasted conditions. After a wash-out period for 14-days, all subjects were rolled over to Part 2 where they received a single dose of 5 mg levamlodipine maleate tablets under a high-fat/high-calorie meal to assess food effect.

Intervention type: DRUG
Group type: OTHER
Intervention: Levamlodipine, Amlodipine
Description: In Part 1, this group of subjects were treated with a single dose of 5 mg levamlodipine maleate tablets (Test Product), then crossed over to receive a single dose of 10 mg Amlodipine Besylate Tablet NORVASC® (Reference Product) under fasted conditions. After a wash-out period for 14-days, all subjects were rolled over to Part 2 where they received a single dose of 5 mg levamlodipine maleate tablets under a high-fat/high-calorie meal to assess food effect.

Intervention type: DRUG
Group type: OTHER
Intervention: Amlodipine, Levamlodipine
Description: In Part 1, this group of subjects were treated with a single dose of 10 mg Amlodipine Besylate Tablet NORVASC® (Reference Product), and then crossed over to receive a single dose of 5 mg levamlodipine maleate tablets (Test Product) under fasted conditions. After a wash-out period for 14-days, all subjects were rolled over to Part 2 where they received a single dose of 5 mg levamlodipine maleate tablets under a high-fat/high-calorie meal to assess food effect.

Intervention type: DRUG
Group type: OTHER
Intervention: Amlodipine, Levamlodipine
Description: In Part 1, this group of subjects were treated with a single dose of 10 mg Amlodipine Besylate Tablet NORVASC® (Reference Product), and then crossed over to receive a single dose of 5 mg levamlodipine maleate tablets (Test Product) under fasted conditions. After a wash-out period for 14-days, all subjects were rolled over to Part 2 where they received a single dose of 5 mg levamlodipine maleate tablets under a high-fat/high-calorie meal to assess food effect.
Study: NCT00893685

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wireless monitors for disease specific clinical parameters.
Description: Homes of participants will be equipped with wireless monitors for blood pressure, blood oxygen, blood glucose, peak expiratory flow, electrocardiogram, body weight. All vital parameters are monitored on a continuous, at least daily basis and obtained values are transmitted to a monitoring centre. Abnormal values are classified for their health risk and health alarms and/or intervention of health professionals is triggered.
Study: NCT00455312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath 1H
Description: 10, 9, 8, 7, and 6 days before transplant subjects will be given 1 dose of campath 1H given via catheter (0.2 mg/kg over 2 hours).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 7 days before the transplant, 1 dose of cyclophosphamide is given via catheter (50mg/kg IV over 2 hours).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 7 days before the transplant, 1 dose of cyclophosphamide is given via catheter (50mg/kg IV over 2 hours).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 6, 5, 4, 3, and 2 days before the transplant, 1 dose fludarabine is given via catheter (40 mg/kg IV over 1 hour)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 6, 5, 4, 3, and 2 days before the transplant, 1 dose fludarabine is given via catheter (40 mg/kg IV over 1 hour)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: 1 day before the transplant one dose (200 cGy) of total body irradiation is given

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: 1 day before the transplant one dose (200 cGy) of total body irradiation is given

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplantation
Description: Infusion of stem cells on Day 0.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplantation
Description: Infusion of stem cells on Day 0.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antithymocyte globulin
Description: ATG (rabbit) 3 mg/kg for 3 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: 2mg/kg IV is given before each dose of antithymocyte globulin (ATG).
Study: NCT00886522

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intrabone cord blood infusion
Description: Myeloablative conditioning regimen (MAC):~i.v. Busulfan 12.8 mg/kg, Cyclophosphamide 120 mg/kg, ATG-Fresenius 30 mg/kg~Reduced intensity conditioning regimen (RIC):~Tiothepa 10 mg/kg, Fludarabine 100 mg/kg, Cyclophosphamide 100 mg/kg, ATG-Fresenius 30 mg/kg~GVHD prophylaxis:~Cyclosporine 1 mg/kg since day -7 to +120, Mycophenolate 15 mg kg x 2 since day +1 to +27
Study: NCT02903407

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: IV midazolam will be administered as a continuous infusion to maintain set goal sedation level of RASS 0 to -2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: IV propofol will be administered as a continuous infusion to maintain set goal sedation level of RASS 0 to -2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: IV dexmedetomidine will be administered as a continuous infusion to maintain set goal sedation level of RASS 0 to -2.
Study: NCT00627016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole
Description: 30 mg capsule, orally, once daily for 4 weeks
Study: NCT03097536

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Luna Bar
Description: Luna Bar (blueberry bliss or lemon zest flavor) product of Clif
Study: NCT00747058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-3864086
Description: The dosage form is POS (powdered oral suspension). Each subject will have 5 periods and the frequency (and duration) is once per period. The doses have been left flexible within the protocol but are listed as: 3, 10, 30, 60, 120, 240, 480 and 720 mg with an option to insert an additional dose cohort as well.
Study: NCT02957773

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Daily activities
Description: Participants do their daily activities routine for 90-minutes, such as watching television, reading and sitting together or participants can do free individual activities on their own.
Study: NCT05674773

Intervention type: PROCEDURE
Intervention: Endoscopic or surgical resection
Description: endoscopic or surgical (partial, (sub)total, proctocolectomy) resection
Study: NCT00627016

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule, orally, once daily for 4 weeks
Study: NCT00910052

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tisseelä fibrin sealant
Description: Fibrin sealant applied intraoperatively
Study: NCT03792958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM082
Description: CM082 tablets taken orally 200、400、600 and 800 mg (QD or BID)